There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ACADIA Pharmaceuticals (ACAD) and Aptose Biosciences (APTO) with bullish sentiments.
ACADIA Pharmaceuticals (ACAD)
In a report released yesterday, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on ACADIA Pharmaceuticals, with a price target of $56.00. The company’s shares closed last Monday at $40.22.
According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of 13.3% and a 43.8% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Zynerba Pharmaceuticals.
ACADIA Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $58.86, representing a 43.8% upside. In a report issued on February 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.
See today’s analyst top recommended stocks >>
Aptose Biosciences (APTO)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Aptose Biosciences, with a price target of $13.00. The company’s shares closed last Monday at $7.73.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 13.5% and a 43.5% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Atara Biotherapeutics.
Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $10.60, representing a 37.3% upside. In a report issued on February 20, Maxim Group also initiated coverage with a Buy rating on the stock with a $16.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
